Rituximab in ANCA-associated vasculitis presenting with severe acute kidney injury; a case report
Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis presenting with severe acute kidney injury (AKI), consistent with rapidly progressive glomerulonephritis portends significant renal morbidity with up to 20%–25% of patients reaching end stage renal disease within a few years after dia...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Society of Diabetic Nephropathy Prevention
2019-01-01
|
| Series: | Journal of Nephropharmacology |
| Subjects: | |
| Online Access: | http://jnephropharmacology.com/PDF/npj-8-13.pdf |
| _version_ | 1811248927907774464 |
|---|---|
| author | Macaulay Onuigbo Julius Seok Ikenna Anyamene Fortunate Ejimone Chinenye Eze-Raphael In-Ah Vanessa Park |
| author_facet | Macaulay Onuigbo Julius Seok Ikenna Anyamene Fortunate Ejimone Chinenye Eze-Raphael In-Ah Vanessa Park |
| author_sort | Macaulay Onuigbo |
| collection | DOAJ |
| description | Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis presenting with severe
acute kidney injury (AKI), consistent with rapidly progressive glomerulonephritis portends
significant renal morbidity with up to 20%–25% of patients reaching end stage renal disease
within a few years after diagnosis. Nevertheless, a smaller proportion of patients require
dialysis at presentation or within the first six months. There is still some debate as to the first
line therapy of choice for such patients vis a vis the use of the newer agent rituximab versus the
time-tested cyclophosphamide in combination with glucocorticoids. Our recent experience at
The Robert Larner, M.D. College of Medicine, University of Vermont, Burlington, VT, USA in
June 2018 allowed us to revisit this controversy. |
| first_indexed | 2024-04-12T15:37:35Z |
| format | Article |
| id | doaj.art-2d4efb09a7b84dd3ac451b7fb51ff91d |
| institution | Directory Open Access Journal |
| issn | 2345-4202 |
| language | English |
| last_indexed | 2024-04-12T15:37:35Z |
| publishDate | 2019-01-01 |
| publisher | Society of Diabetic Nephropathy Prevention |
| record_format | Article |
| series | Journal of Nephropharmacology |
| spelling | doaj.art-2d4efb09a7b84dd3ac451b7fb51ff91d2022-12-22T03:26:55ZengSociety of Diabetic Nephropathy PreventionJournal of Nephropharmacology2345-42022019-01-0181131310.15171/npj.2019.13npj-20190126132442Rituximab in ANCA-associated vasculitis presenting with severe acute kidney injury; a case reportMacaulay Onuigbo0Julius Seok1Ikenna Anyamene2Fortunate Ejimone3Chinenye Eze-Raphael4In-Ah Vanessa Park5The Robert Larner, M.D. College of Medicine, University of Vermont, Burlington, VT, USAThe Robert Larner, M.D. College of Medicine, University of Vermont, Burlington, VT, USAUniversity of Port Harcourt Teaching Hospital, Port Harcourt, NigeriaNnamdi Azikiwe University Teaching Hospital, Nnewi, NigeriaUniversity of Nigeria Teaching Hospital, Enugu, NigeriaThe Robert Larner, M.D. College of Medicine, University of Vermont, Burlington, VT, USAAnti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis presenting with severe acute kidney injury (AKI), consistent with rapidly progressive glomerulonephritis portends significant renal morbidity with up to 20%–25% of patients reaching end stage renal disease within a few years after diagnosis. Nevertheless, a smaller proportion of patients require dialysis at presentation or within the first six months. There is still some debate as to the first line therapy of choice for such patients vis a vis the use of the newer agent rituximab versus the time-tested cyclophosphamide in combination with glucocorticoids. Our recent experience at The Robert Larner, M.D. College of Medicine, University of Vermont, Burlington, VT, USA in June 2018 allowed us to revisit this controversy.http://jnephropharmacology.com/PDF/npj-8-13.pdfAcute kidney injuryAnti-neutrophil cytoplasmic antibodyRituximabVasculitisAcute kidney injuryPulmonary-renal syndrome |
| spellingShingle | Macaulay Onuigbo Julius Seok Ikenna Anyamene Fortunate Ejimone Chinenye Eze-Raphael In-Ah Vanessa Park Rituximab in ANCA-associated vasculitis presenting with severe acute kidney injury; a case report Journal of Nephropharmacology Acute kidney injury Anti-neutrophil cytoplasmic antibody Rituximab Vasculitis Acute kidney injury Pulmonary-renal syndrome |
| title | Rituximab in ANCA-associated vasculitis presenting
with severe acute kidney injury; a case report |
| title_full | Rituximab in ANCA-associated vasculitis presenting
with severe acute kidney injury; a case report |
| title_fullStr | Rituximab in ANCA-associated vasculitis presenting
with severe acute kidney injury; a case report |
| title_full_unstemmed | Rituximab in ANCA-associated vasculitis presenting
with severe acute kidney injury; a case report |
| title_short | Rituximab in ANCA-associated vasculitis presenting
with severe acute kidney injury; a case report |
| title_sort | rituximab in anca associated vasculitis presenting with severe acute kidney injury a case report |
| topic | Acute kidney injury Anti-neutrophil cytoplasmic antibody Rituximab Vasculitis Acute kidney injury Pulmonary-renal syndrome |
| url | http://jnephropharmacology.com/PDF/npj-8-13.pdf |
| work_keys_str_mv | AT macaulayonuigbo rituximabinancaassociatedvasculitispresentingwithsevereacutekidneyinjuryacasereport AT juliusseok rituximabinancaassociatedvasculitispresentingwithsevereacutekidneyinjuryacasereport AT ikennaanyamene rituximabinancaassociatedvasculitispresentingwithsevereacutekidneyinjuryacasereport AT fortunateejimone rituximabinancaassociatedvasculitispresentingwithsevereacutekidneyinjuryacasereport AT chinenyeezeraphael rituximabinancaassociatedvasculitispresentingwithsevereacutekidneyinjuryacasereport AT inahvanessapark rituximabinancaassociatedvasculitispresentingwithsevereacutekidneyinjuryacasereport |